EXTOD-Immune
This study is investigating whether a home-based exercise programme can help people recently diagnosed with type 1 diabetes (T1D) slow down the progression of the disease.
It is part of the Exercise for Type 1 Diabetes (EXTOD) programme, which aims to provide evidence-based support for people living with diabetes to be able to undertake safe and effective exercise.
The study is being led by a team of researchers at the University of Birmingham.
Criteria
- Aged 18+
- Diagnosed with type 1 diabetes in the last three years
- Self-administer insulin as part of an injection regime or insulin pump.
- Able to exercise safely, recognise symptoms of low blood sugar, and understand the principles of dose adjustment in relation to carbohydrates.
Location
- Exercise programme – remote and online
- Face-to-face appointments – at one of four local clinical research facilities:
- Liverpool John Moores University, Liverpool
- Queen Elizabeth Hospital, Birmingham
- Musgrove Park Hospital, Taunton
- Royal Free Hospital, London
Involves
- following a 12-week home-based exercise programme*
- Four visits to a local Clinical Research Facility over a 36-week period, to include a range of tests (eg fasting bloods samples, body measurements etc), as well as questionnaires about lifestyle and barriers to exercise.
- Wearing a continuous glucose monitor to track blood sugar levels for 14 days on four occasions.
- Downloading and using the Polar Flow training app on their own smartphone.
All participants will have their general and clinical health measured as part of the study and will receive advice on the best kinds of exercise to benefit their health and T1D.
Participants will receive a £50 Amazon voucher a the end of the study. Reasonable travel expenses will be reimbursed.
* Participants will be randomly assigned to one of two groups; the control group, who will continue with normal lifestyle or the home-based exercise group. Following a 12-week break participants will then be assigned to the other group.
Recruiting until
- 31 December 2023
Share this study